1. Generics Bulletin
  2. >>Business

Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend

Regions Seek To Bolster Domestic Production Capacity As Weaknesses Exposed

 
• By Dave Wallace

Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.

World map texture in a dried and cracked soil with Pandemic Perspectives logo
The past year has exposed fragility in the global supply chain • Source: Shutterstock
Pandemic Perspectives

One year on from the World Health Organization declaring COVID-19 a global pandemic, editors across our publications are taking a closer look at its impact and possible lasting implications for pharma and medtech.

One year on from the formal designation by the World Health Organization of the coronavirus outbreak as a pandemic, the disruptive effects on the global pharmaceutical supply chain,

For years, the pharmaceuticals industry and the generics industry in particular have become increasingly reliant on supplies of ingredients and formulations from specific geographies in Asia, notably India and China, with the globalization of the supply network

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.